Skip to main content
Top
Published in: Supportive Care in Cancer 11/2015

01-11-2015 | Original Article

Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients

Authors: Sebastiano Mercadante, Federica Aielli, Claudio Adile, Patrizia Ferrera, Alessandro Valle, Flavio Fusco, Amanda Caruselli, Claudio Cartoni, Pizzuto Massimo, Francesco Masedu, Marco Valenti, Giampiero Porzio

Published in: Supportive Care in Cancer | Issue 11/2015

Login to get access

Abstract

Background

Oral symptoms can be a sign of an underlying systemic condition and have a significant impact on quality of life, nutrition, and cost of care, while these lesions are often studied in the context of cancer treatment. However, information regarding oral symptoms in advanced cancer patients is poor. The aim of this multicenter study was to determine the prevalence and the characteristics of oral symptoms in a large population of advanced cancer patients.

Methods

A consecutive sample of patients with advanced cancer for a period of 6 months was prospectively assessed for an observational study. At time of admission, the epidemiological characteristics, surgery-radiotherapy of head and neck, and oncologic treatments in the last month were recorded. The presence of mucositis, dry mouth, and dysphagia was assessed by clinical examination and patients’ report and their intensity recorded. Patients were also asked whether they had limitation on nutrition of hydration due to the local condition.

Results

Six hundred sixty-nine patients were surveyed in the period taken into consideration. The mean age was 72.1 years (SD 12.3), and 342 patients were males. The primary tumors are listed in Table 1. The prevalence of mucositis was 22.3 %. The symptom relevantly reduced the ingestion of food or fluids and was statistically associated with the Karnofsky level and head and neck cancer. The prevalence of dry mouth was 40.4 %, with a mean intensity of 5.4 (SD 2.1). Several drugs were concomitantly given, particularly opioids (78 %), corticosteroids (75.3 %), and diuretics (70.2 %). Various and nonhomogeneous treatments were given for dry mouth, that was statistically associated with current or recent chemotherapy, and hematological tumors. The prevalence of dysphagia was 15.4 % with a mean intensity of 5.34 (SD 3). Dysphagia for liquids was observed in 52.4 % of cases. A high level of limitation for oral nutrition due to dysphagia was found, and in 53.4 % of patients, alternative routes to the oral one were used. Dysphagia was statistically associated with the Karnofsky level and head and neck cancer. A strong relationship between the three oral symptoms was found.

Conclusion

In advanced cancer patients, a range of oral problems significantly may impact on the physical, social, and psychological well-being of advanced cancer patients to varying degrees. These symptoms should be carefully assessed early but become imperative in the palliative care setting when they produce relevant consequences that may be life-threatening other than limiting the daily activities, particularly eating and drinking.
Literature
1.
go back to reference Plemons JM, Al-Hashimi I, Marek CL, American Dental Association Council on Scientific Affairs (2014) Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 145:867–873CrossRefPubMed Plemons JM, Al-Hashimi I, Marek CL, American Dental Association Council on Scientific Affairs (2014) Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 145:867–873CrossRefPubMed
2.
go back to reference Hanchanale S, Adkinson L, Daniel S, Fleming M, Oxberry SG (2015) Systematic literature review: xerostomia in advanced cancer patients. Support Care Cancer 23:881–888 Hanchanale S, Adkinson L, Daniel S, Fleming M, Oxberry SG (2015) Systematic literature review: xerostomia in advanced cancer patients. Support Care Cancer 23:881–888
3.
go back to reference Vadhan-Raj S, Goldberg JD, Perales MA, Berger DP, van den Brink MR (2013) Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. J Cell Mol Med 17:1371–1384PubMedCentralCrossRefPubMed Vadhan-Raj S, Goldberg JD, Perales MA, Berger DP, van den Brink MR (2013) Clinical applications of palifermin: amelioration of oral mucositis and other potential indications. J Cell Mol Med 17:1371–1384PubMedCentralCrossRefPubMed
4.
go back to reference Bogaardt H, Veerbeek L, Kelly K et al (2015) Swallowing problems at the end of the palliative phase: incidence and severity in 164 unsedated patients. Dysphagia. In press Bogaardt H, Veerbeek L, Kelly K et al (2015) Swallowing problems at the end of the palliative phase: incidence and severity in 164 unsedated patients. Dysphagia. In press
5.
go back to reference Lalla RV, Ashbury FD (2013) The MASCC/ISOO mucositis guidelines: dissemination amd clinical impact. Support Care Cancer 21:3161–3163CrossRefPubMed Lalla RV, Ashbury FD (2013) The MASCC/ISOO mucositis guidelines: dissemination amd clinical impact. Support Care Cancer 21:3161–3163CrossRefPubMed
6.
go back to reference Farhangfar A, Makarewicz M, Ghosh S et al (2014) Nutrition impact symptoms in a population cohort of head and neck cancer patients: multivariate regression analysis of symptoms on oral intake, weight loss and survival. Oral Oncol 50:877–883CrossRefPubMed Farhangfar A, Makarewicz M, Ghosh S et al (2014) Nutrition impact symptoms in a population cohort of head and neck cancer patients: multivariate regression analysis of symptoms on oral intake, weight loss and survival. Oral Oncol 50:877–883CrossRefPubMed
7.
go back to reference Wilberg P, Hjermstad MJ, Ottesen S, Herlofson BB (2014) Chemotherapy-associated oral sequelae in patients with cancers outside the head and neck region. J Pain Symptom Manag 48:1060–1069CrossRef Wilberg P, Hjermstad MJ, Ottesen S, Herlofson BB (2014) Chemotherapy-associated oral sequelae in patients with cancers outside the head and neck region. J Pain Symptom Manag 48:1060–1069CrossRef
8.
go back to reference Peterman A, Cella D, Glandon G et al (2001) Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr 29:45–51CrossRefPubMed Peterman A, Cella D, Glandon G et al (2001) Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr 29:45–51CrossRefPubMed
9.
go back to reference Elting LS, Cooksley CD, Chambers MS et al (2007) Risks, outcomes, and costs of radiation-induced otalmucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 68:1110–1120CrossRefPubMed Elting LS, Cooksley CD, Chambers MS et al (2007) Risks, outcomes, and costs of radiation-induced otalmucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 68:1110–1120CrossRefPubMed
10.
go back to reference Trotti A, Bellm LA, Epstein GB et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 6:253–262CrossRef Trotti A, Bellm LA, Epstein GB et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 6:253–262CrossRef
11.
go back to reference Sonis ST (2004) Oral mucositis in cancer therapy. J Support Oncol 2:003–008 Sonis ST (2004) Oral mucositis in cancer therapy. J Support Oncol 2:003–008
12.
go back to reference Fisher DJ, Epstein JB, Yan Y, Wilkie DJ (2014) Oral health conditions affect functional and social activities of terminally ill cancer patients. Support Care Cancer 22:803–810CrossRef Fisher DJ, Epstein JB, Yan Y, Wilkie DJ (2014) Oral health conditions affect functional and social activities of terminally ill cancer patients. Support Care Cancer 22:803–810CrossRef
13.
go back to reference Oneschuk D, Hanson J, Bruera E (2000) A survey of mouth pain and dryness in patients with advanced cancer. Support Care Cancer 8:372–376CrossRefPubMed Oneschuk D, Hanson J, Bruera E (2000) A survey of mouth pain and dryness in patients with advanced cancer. Support Care Cancer 8:372–376CrossRefPubMed
14.
go back to reference Goldstein NE, Genden E, Morrison RS (2008) Palliative care for patients with head and neck cancer: "I would like a quick return to a normal lifestyle". JAMA 2991818–25 Goldstein NE, Genden E, Morrison RS (2008) Palliative care for patients with head and neck cancer: "I would like a quick return to a normal lifestyle". JAMA 2991818–25
15.
go back to reference Sigurdardottir KR, Haugen DF (2008) Prevalence of distressing symptoms in hospitalised patients on medical wards: a cross-sectional study. BMC Palliat Care 7:16PubMedCentralCrossRefPubMed Sigurdardottir KR, Haugen DF (2008) Prevalence of distressing symptoms in hospitalised patients on medical wards: a cross-sectional study. BMC Palliat Care 7:16PubMedCentralCrossRefPubMed
16.
go back to reference Al-Shahri MZ, Eldali AM, Al-Zahrani O (2012) Non pain symptoms of new and follow-up cancer patients attending a palliative careoutpatient clinic in Saudi Arabia. Indian J Palliat Care 18:98–102PubMedCentralCrossRefPubMed Al-Shahri MZ, Eldali AM, Al-Zahrani O (2012) Non pain symptoms of new and follow-up cancer patients attending a palliative careoutpatient clinic in Saudi Arabia. Indian J Palliat Care 18:98–102PubMedCentralCrossRefPubMed
17.
go back to reference Tsai JS, Wu CH, Chiu TY, Hu WY, Chen CY (2006) Symptom patterns of advanced cancer patients in a palliative care unit. Palliat Med 20:617–622CrossRefPubMed Tsai JS, Wu CH, Chiu TY, Hu WY, Chen CY (2006) Symptom patterns of advanced cancer patients in a palliative care unit. Palliat Med 20:617–622CrossRefPubMed
18.
go back to reference Morita T, Tsunoda J, Inoue S, Chihara S (1999) Contributing factors to physical symptoms in terminally-ill cancer patients. J Pain Symptom Manag 18:338–346CrossRef Morita T, Tsunoda J, Inoue S, Chihara S (1999) Contributing factors to physical symptoms in terminally-ill cancer patients. J Pain Symptom Manag 18:338–346CrossRef
19.
go back to reference Maltoni M, Caraceni A, Brunelli C et al (2005) Steering Committee of the European Association for Palliative Care Prognostic factors in advanced cancer patients: evidence-based clinical recommendations-a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23:6240–6248CrossRefPubMed Maltoni M, Caraceni A, Brunelli C et al (2005) Steering Committee of the European Association for Palliative Care Prognostic factors in advanced cancer patients: evidence-based clinical recommendations-a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23:6240–6248CrossRefPubMed
20.
go back to reference Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 8:175–179CrossRefPubMed Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 8:175–179CrossRefPubMed
21.
go back to reference Mercadante S, Casuccio A, Fulfaro F (2000) The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manag 20:104–112CrossRef Mercadante S, Casuccio A, Fulfaro F (2000) The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manag 20:104–112CrossRef
23.
go back to reference Nabal M, Bescos M, Barcons M et al (2014) New symptom-based predictive tool for survival at seven and thirty days developed by palliative home care teams. J Palliat Med 17:1158–1163CrossRefPubMed Nabal M, Bescos M, Barcons M et al (2014) New symptom-based predictive tool for survival at seven and thirty days developed by palliative home care teams. J Palliat Med 17:1158–1163CrossRefPubMed
24.
go back to reference Gwilliam B, Keeley V, Todd C (2011) Development of prognosis in palliative care study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ Aug 25:343 Gwilliam B, Keeley V, Todd C (2011) Development of prognosis in palliative care study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ Aug 25:343
25.
go back to reference Alt-Epping B, Nejad RK, Jung K, Gross U, Nauck F (2012) Symptoms of the oral cavity and their association with local microbiological and clinical findings—a prospective survey in palliative care. Support Care Cancer 20:531–537PubMedCentralCrossRefPubMed Alt-Epping B, Nejad RK, Jung K, Gross U, Nauck F (2012) Symptoms of the oral cavity and their association with local microbiological and clinical findings—a prospective survey in palliative care. Support Care Cancer 20:531–537PubMedCentralCrossRefPubMed
26.
go back to reference Rohr Y, Adams J, Young L (2010) Oral discomfort in palliative care: results of an exploratory study of the experiences of terminally ill patients. Int J Palliat Nurs 16:439–444CrossRefPubMed Rohr Y, Adams J, Young L (2010) Oral discomfort in palliative care: results of an exploratory study of the experiences of terminally ill patients. Int J Palliat Nurs 16:439–444CrossRefPubMed
Metadata
Title
Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients
Authors
Sebastiano Mercadante
Federica Aielli
Claudio Adile
Patrizia Ferrera
Alessandro Valle
Flavio Fusco
Amanda Caruselli
Claudio Cartoni
Pizzuto Massimo
Francesco Masedu
Marco Valenti
Giampiero Porzio
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2720-y

Other articles of this Issue 11/2015

Supportive Care in Cancer 11/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine